Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma-1

Els were negative correlated with the levels of RhoA protein in HCC with adjusted -0.447 and two-tailed probability, n = 53, = 0.01.<p><b>Copyright information:</b></p><p>Taken from "Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma"</p><p>http://www.biomedcentral.com/1471-2407/8/205</p><p>BMC Cancer 2008;8():205-205.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496915.</p><p></p

Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma-3

S of DLC2 protein than PCLT. = 0.02.<p><b>Copyright information:</b></p><p>Taken from "Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma"</p><p>http://www.biomedcentral.com/1471-2407/8/205</p><p>BMC Cancer 2008;8():205-205.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496915.</p><p></p

Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma-2

H expression confirmed by Western blotting was used as positive controls (), whereas negative controls were done by omitting the primary antibody (). The representative positive expression of DLC2 () and negative expression of DLC2 () in HCC specimens were presented. Kaplan-Meier survival curves for DLC2-positive expression group (n = 33) and DLC2-negative expression group (n = 95) based on results of immunohistochemistry (). HCC patients with DLC2-negative expression revealed significant poor prognosis than those with DLC2-positive expression, Log-rank test, = 0.003.<p><b>Copyright information:</b></p><p>Taken from "Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma"</p><p>http://www.biomedcentral.com/1471-2407/8/205</p><p>BMC Cancer 2008;8():205-205.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496915.</p><p></p

Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma-0

S of DLC2 protein than PCLT. = 0.02.<p><b>Copyright information:</b></p><p>Taken from "Underexpression of Deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma"</p><p>http://www.biomedcentral.com/1471-2407/8/205</p><p>BMC Cancer 2008;8():205-205.</p><p>Published online 23 Jul 2008</p><p>PMCID:PMC2496915.</p><p></p